文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病患者单倍体干细胞供者选择:来自EBMT急性白血病工作组的研究

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性分析纳入2200例接受移植后环磷酰胺预防GVHD的单倍体造血干细胞移植的急性髓系白血病患者,评估供者特征对结局的影响。多变量分析发现,使用外周血、供者年龄>37岁、女性供者用于男性受者负向影响GRFS;供者年龄及女性供者-男性受者组合也影响非复发死亡、无白血病生存和总生存。结论认为供者相关变量显著影响结局,应优先选择年轻供者和男性受者的男性供者,使用骨髓可预防GVHD。

要点

  • 使用外周血、供者年龄>37岁、女性供者用于男性受者负向影响GRFS。
  • 供者年龄及女性供者-男性受者组合也影响非复发死亡、无白血病生存和总生存。
  • 作者认为应优先选择年轻供者和男性受者的男性供者,使用骨髓可预防GVHD。

核心结论

  • 供者相关变量显著影响接受移植后环磷酰胺预防GVHD的单倍体造血干细胞移植的急性髓系白血病患者的结局。
  • 作者认为,当可能时,应优先选择年轻供者和男性受者的男性供者;使用骨髓可额外预防GVHD。

研究设计与样本

  • 欧洲血液与骨髓移植学会急性白血病工作组的回顾性分析,评估单倍体供者特征对接受移植后环磷酰胺预防GVHD的急性髓系白血病患者结局的影响。
  • 共纳入2200例患者;供者中位年龄37岁(范围8-71);820例(37%)为女性,其中458例(21%)用于男性受者;1631例供者(74%)捐献外周血。
  • 主要终点为无GVHD且无复发生存(GRFS)。

主要发现

  • 多变量分析确定某些供者相关危险因素对移植结局有不利影响。
  • 使用外周血、供者年龄>37岁、女性供者用于男性受者负向影响GRFS。
  • 供者年龄和女性供者-男性受者组合也影响非复发死亡、无白血病生存和总生存。

临床怎么用

  • 作者认为,当可能时,应优先选择年轻供者和男性受者的男性供者。
  • 作者认为,使用骨髓可额外预防GVHD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sanz J, Labopin M, Blaise D, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024. PMID: 38429091. doi:10.1182/bloodadvances.2023012133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。